Targeting the JNK-JUN pathway to overcome therapy resistance in melanoma

黑色素瘤患者对靶向治疗和免疫治疗有显著反应。然而，大多数患者在靶向治疗方面进展迅速，只有一小部分患者对免疫治疗有反应。我们发现与JNK抑制剂联合治疗可以克服治疗耐药性。我们将确定可用的最有效的JNK抑制剂，以及最佳剂量和联合治疗计划，以评估患者改善反应，结果和生存率。

Melanoma patients can display remarkable responses to targeted and immunotherapies. However most patients progress rapidly on targeted therapies and only a small proportion respond to immunotherapies. We have found that combination treatment with JNK inhibitors can overcome therapy resistance. We will determine the most efficacious JNK inhibitors available, and the optimal dosing and scheduling of combination treatment for evaluation in patients to improve responses, outcomes and survival.